NO991449L - Antistoff mot human parathormon-relaterte peptider - Google Patents

Antistoff mot human parathormon-relaterte peptider

Info

Publication number
NO991449L
NO991449L NO991449A NO991449A NO991449L NO 991449 L NO991449 L NO 991449L NO 991449 A NO991449 A NO 991449A NO 991449 A NO991449 A NO 991449A NO 991449 L NO991449 L NO 991449L
Authority
NO
Norway
Prior art keywords
antibody
related peptides
human parathormone
parathormone
human
Prior art date
Application number
NO991449A
Other languages
English (en)
Other versions
NO991449D0 (no
Inventor
Koh Sato
Yuji Wakahara
Naohiro Yabuta
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO991449D0 publication Critical patent/NO991449D0/no
Publication of NO991449L publication Critical patent/NO991449L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO991449A 1996-09-26 1999-03-25 Antistoff mot human parathormon-relaterte peptider NO991449L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP25519696 1996-09-26
JP21416897 1997-07-24
PCT/JP1997/003382 WO1998013388A1 (fr) 1996-09-26 1997-09-24 Anticorps contre les peptides lies a la parathormone humaine

Publications (2)

Publication Number Publication Date
NO991449D0 NO991449D0 (no) 1999-03-25
NO991449L true NO991449L (no) 1999-05-25

Family

ID=26520176

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991449A NO991449L (no) 1996-09-26 1999-03-25 Antistoff mot human parathormon-relaterte peptider

Country Status (17)

Country Link
US (3) US6903194B1 (no)
EP (1) EP0962467A4 (no)
KR (1) KR100847441B1 (no)
CN (1) CN100335501C (no)
AU (1) AU744146B2 (no)
BR (1) BR9713294A (no)
CA (1) CA2266332C (no)
CZ (1) CZ106299A3 (no)
HK (1) HK1096974A1 (no)
HU (1) HUP9904177A3 (no)
IL (1) IL129164A (no)
NO (1) NO991449L (no)
RU (1) RU2198220C2 (no)
SK (1) SK40599A3 (no)
TR (1) TR199900666T2 (no)
TW (1) TW509697B (no)
WO (1) WO1998013388A1 (no)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0962467A4 (en) 1996-09-26 2002-10-30 Chugai Pharmaceutical Co Ltd ANTIBODIES AGAINST HUMAN PARATHORMON RELATED PEPTIDES
ATE361099T1 (de) 1997-05-15 2007-05-15 Chugai Pharmaceutical Co Ltd Heilmittel für kachexie
CA2332128A1 (en) * 1998-06-26 2000-01-06 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hypercalcemic crisis
KR20020013538A (ko) 1999-05-10 2002-02-20 나가야마 오사무 세포의 배양방법
CA2373885A1 (en) * 1999-07-02 2001-01-11 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for diseases caused by pth or pthrp
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
CA2373945A1 (en) * 1999-07-06 2001-01-11 Chugai Seiyaku Kabushiki Kaisha Remedies for drug-resistant hypercalcemia
KR20030008205A (ko) 1999-10-01 2003-01-24 추가이 세이야쿠 가부시키가이샤 혈액응고 관련 질환의 예방 및 치료
US20030124119A1 (en) * 1999-12-28 2003-07-03 Tadao Yamazaki Stable antibody compositions and injection preparations
WO2001054725A1 (fr) * 2000-01-25 2001-08-02 Chugai Seiyaku Kabushiki Kaisha Remèdes et agents prophylactiques pour maladies dentaires
WO2001064249A1 (en) * 2000-02-28 2001-09-07 Chugai Seiyaku Kabushiki Kaisha Tissue decomposition inhibitor
EP1283057B2 (en) * 2000-04-28 2012-05-30 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
EP1849479A1 (en) * 2000-08-16 2007-10-31 Chugai Seiyaku Kabushiki Kaisha Ameliorating agent for symptoms resulting from joint diseases
WO2002052005A1 (fr) 2000-12-22 2002-07-04 Kazusa Dna Research Institute Foundation Genes et proteines codees par ceux-ci
EP3088412B1 (en) * 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Protein purification method
US20040213788A1 (en) * 2001-05-18 2004-10-28 Sweet Raymond W. Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US8949082B2 (en) 2001-11-02 2015-02-03 Siemens Medical Solutions Usa, Inc. Healthcare information technology system for predicting or preventing readmissions
WO2003040878A2 (en) * 2001-11-02 2003-05-15 Siemens Medical Solutions Usa, Inc. Patient data mining for clinical trials
US7457731B2 (en) 2001-12-14 2008-11-25 Siemens Medical Solutions Usa, Inc. Early detection of disease outbreak using electronic patient data to reduce public health threat from bio-terrorism
US20050118163A1 (en) 2002-02-14 2005-06-02 Hidefumi Mizushima Antibody-containing solution pharmaceuticals
FR2841788B1 (fr) * 2002-07-05 2006-01-27 Univ Pasteur Utilisation d'antagonistes de la pthrp pour traiter le carcinome a cellules renales
US20060058511A1 (en) 2002-08-27 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing protein solution preparation
WO2004022595A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha MRL/lprマウスを用いた抗体の作製
US7680086B2 (en) * 2002-09-09 2010-03-16 Siemens Canada Limited Wireless local area network with clients having extended freedom of movement
ES2626268T3 (es) 2002-09-11 2017-07-24 Chugai Seiyaku Kabushiki Kaisha Método de purificación de proteínas
WO2004043405A2 (en) * 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
AU2003262273A1 (en) * 2002-11-18 2004-06-15 Chugai Seiyaku Kabushiki Kaisha Remedy for chondroma or chondrosarcoma
US20080153104A1 (en) 2003-08-08 2008-06-26 Hiroyuki Aburantai Gene Overexpressed in Cancer
SI1745075T1 (sl) 2004-04-21 2013-07-31 The Brigham And Women's Hospital, Inc. Poli-N-acetilglukozamin (PNAG/dPNAG) vezavni peptidi in postopki za njihovo uporabo
CN111925445A (zh) 2004-07-09 2020-11-13 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
EP3623473A1 (en) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US20080275731A1 (en) * 2005-05-18 2008-11-06 Rao R Bharat Patient data mining improvements
WO2006132341A1 (ja) * 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2部位特異的変異体
CA2610987C (en) * 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
JP2008546716A (ja) * 2005-06-17 2008-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ＧＦＲα３抗体
EP1947180B1 (en) 2005-10-18 2012-12-05 National Institute Of Agrobiological Sciences Antibody producing transgenic silkworms and method for producing the same
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
WO2007129457A1 (ja) 2006-04-25 2007-11-15 The University Of Tokyo アルツハイマー病および癌の治療薬
MX2008015975A (es) 2006-06-14 2009-03-26 Chugai Pharmaceutical Co Ltd Agentes para promocionar el crecimiento de celulas de vastago hematopoyeticas.
EP2093237B1 (en) 2006-10-20 2015-12-30 Chugai Seiyaku Kabushiki Kaisha Anti-cancer agent comprising anti-hb-egf antibody as active ingredient
EP2078731A4 (en) 2006-10-20 2012-08-01 Forerunner Pharma Res Co Ltd PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
WO2008093688A1 (ja) 2007-01-30 2008-08-07 Forerunner Pharma Research Co., Ltd. キメラFcγレセプター及び該レセプターを用いたＡＤＣＣ活性測定方法
US8501929B2 (en) 2007-08-17 2013-08-06 Biochrom Pharma Inc. PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease
US7897139B2 (en) * 2007-08-17 2011-03-01 Biochrom Pharma, Inc. PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
RU2445366C2 (ru) 2007-09-28 2012-03-20 Чугаи Сейяку Кабусики Кайся Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме
EP2236604B1 (en) 2007-12-05 2016-07-06 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody and use thereof
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
TWI564021B (zh) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
KR101785373B1 (ko) * 2008-07-21 2017-10-16 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
EP2359852A4 (en) 2008-11-17 2015-05-20 Nat Cancer Ct NEW CANCERED THERAPY WITH A SUBSTANCE COMPLEX SPECIFICALLY BINDING TO A TUMOR STREAM FACTOR AND ANTITUMIR COMPOUND
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
MX2011012136A (es) 2009-05-15 2012-04-10 Chugai Pharmaceutical Co Ltd Anticuerpo anti-axl.
AU2010285974A1 (en) 2009-08-17 2012-03-22 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
US8751495B2 (en) * 2009-09-29 2014-06-10 Siemens Medical Solutions Usa, Inc. Automated patient/document identification and categorization for medical data
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
US20110184761A1 (en) * 2010-01-25 2011-07-28 Siemens Medical Solutions Usa, Inc. Method and Apparatus for Estimating Patient Populations
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
US10943676B2 (en) 2010-06-08 2021-03-09 Cerner Innovation, Inc. Healthcare information technology system for predicting or preventing readmissions
EP2658970B1 (en) * 2010-12-31 2016-09-28 Bioatla LLC Express humanization of antibodies
BR112013017585A2 (pt) 2011-01-10 2020-11-24 The Regents Of The University Of Michigan inibidor do fator de células-tronco
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
EP3235557A1 (en) 2011-09-01 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
EP2749641B1 (en) 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
JP6291254B2 (ja) 2011-10-28 2018-03-14 中外製薬株式会社 癌幹細胞特異的分子
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
WO2013161814A1 (ja) 2012-04-23 2013-10-31 ジーンフロンティア株式会社 抗ヒトｃｄ６９抗体、及びその医薬用途
EA031631B1 (ru) 2012-09-27 2019-01-31 Чугаи Сеияку Кабушики Каиша Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения
US10403391B2 (en) 2012-09-28 2019-09-03 Cerner Health Services, Inc. Automated mapping of service codes in healthcare systems
US10318635B2 (en) 2012-09-28 2019-06-11 Cerner Innovation, Inc. Automated mapping of service codes in healthcare systems
US10565315B2 (en) 2012-09-28 2020-02-18 Cerner Innovation, Inc. Automated mapping of service codes in healthcare systems
EP3473718A1 (en) 2012-11-09 2019-04-24 GeneFrontier Corporation Anti-adam28 antibody for treating cancer
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
US10540448B2 (en) 2013-07-15 2020-01-21 Cerner Innovation, Inc. Gap in care determination using a generic repository for healthcare
DK3050896T3 (da) 2013-09-27 2021-07-19 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af en polypeptid-heteromultimer
EP3057992B1 (en) 2013-10-15 2024-04-17 GeneFrontier Corporation Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
TW201609093A (zh) 2013-12-27 2016-03-16 Chugai Pharmaceutical Co Ltd Ｆｇｆｒ門控蛋白變異基因及以其爲標的之醫藥
BR112016014824A2 (pt) 2013-12-27 2017-09-19 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo que tem ponto isoelétrico baixo
SG10201808565QA (en) 2014-03-31 2018-11-29 Debiopharm Int Sa Fgfr fusions
EP4056993A1 (en) 2014-08-20 2022-09-14 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
KR102538745B1 (ko) 2015-09-18 2023-06-01 추가이 세이야쿠 가부시키가이샤 Il-8에 결합하는 항체 및 그의 사용
CN116396393A (zh) 2015-10-08 2023-07-07 酵活英属哥伦比亚省公司 包含κ和λ轻链的抗原结合多肽构建体及其用途
WO2019074124A1 (en) 2017-10-12 2019-04-18 Keio University MONOCLONAL ANTI-AQP3 ANTIBODY BINDING SPECIFICALLY TO THE EXTRACELLULAR DOMAIN OF AQUAPORIN 3 (AQP3) AND USE THEREOF
CN112512480A (zh) 2018-05-21 2021-03-16 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
US11708186B2 (en) 2018-05-28 2023-07-25 Chugai Seiyaku Kabushiki Kaisha Filling nozzle
KR20210015898A (ko) 2018-05-31 2021-02-10 시오노기세이야쿠가부시키가이샤 Nav1.7 모노클로날 항체
WO2020138489A1 (ja) 2018-12-27 2020-07-02 塩野義製薬株式会社 新規抗ｃｃｒ８抗体
WO2020213084A1 (en) 2019-04-17 2020-10-22 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
WO2022004760A1 (ja) 2020-06-30 2022-01-06 塩野義製薬株式会社 抗ｃｃｒ８抗体と化学療法剤の併用
JPWO2023058723A1 (no) 2021-10-08 2023-04-13
WO2023074888A1 (ja) 2021-11-01 2023-05-04 塩野義製薬株式会社 新規なＮａｖ１．７モノクローナル抗体
CN115466331B (zh) 2021-11-18 2023-05-30 合源生物科技(天津)有限公司 靶向bcma的嵌合抗原受体及其应用
CN115109161B (zh) * 2022-06-28 2023-08-11 广东赛尔生物科技有限公司 含有间充质干细胞的减肥药物组合物
WO2024123822A1 (en) * 2022-12-05 2024-06-13 Biogate Precision Medicine Corp. Recombinant antibody, pharmaceutical composition comprising the same, and uses thereof in treating cancers

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5001223A (en) 1987-05-26 1991-03-19 Merck & Co., Inc. Parathyroid hormone antagonists with enhanced metabolic properties
EP0293158A3 (en) 1987-05-26 1990-05-09 Merck & Co. Inc. Parathyroid hormone antagonists
EP0293130A3 (en) 1987-05-26 1990-06-13 Merck & Co. Inc. Dimers of parathyroid hormone antagonists
US4771124A (en) * 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
EP0417191B1 (en) 1988-05-27 1993-03-10 Centocor, Inc. Formulation for antibody reagents
EP0417193B1 (en) 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5217896A (en) 1988-12-30 1993-06-08 Oncogene Science, Inc. Monoclonal antibodies recognizing parathyroid hormone-like protein
JPH02207099A (ja) 1989-02-07 1990-08-16 Tonen Corp ＰＴＨｒＰ関連ペプチド、その製造法及び用途
CA2035179C (en) 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
JPH04228089A (ja) * 1990-05-15 1992-08-18 Kanegafuchi Chem Ind Co Ltd 高カルシウム血症治療・予防剤
JPH05509098A (ja) 1990-07-13 1993-12-16 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア ３，６または９位において変性されている副甲状腺ホルモン類似体
DE4034612A1 (de) * 1990-10-31 1992-05-07 Huels Chemische Werke Ag Verfahren zur herstellung von methacryloxy- oder acryloxygruppen enthaltenden organosilanen
JP3464796B2 (ja) 1991-04-05 2003-11-10 ザ ジェネラル ホスピタル コーポレーション 副甲状腺ホルモンのレセプターとそれをコードしているｄｎａ
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
DE4137744C2 (de) * 1991-11-15 1996-10-31 Kuesters Eduard Maschf Verfahren zum Herstellen eines Schichtwerkstoffs unter Wiederverwendung von Kunststoffabfällen und eigensteifer, Kunstsoffabfälle enthaltender Schichtwerkstoff
DE69232669T2 (de) 1991-12-20 2003-02-27 Yamanouchi Pharma Co Ltd Mit gp11b/iiia reaktive humane antikörper
US5993617A (en) * 1991-12-26 1999-11-30 Asahi Glass Company Ltd. Functional product
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
JP3504697B2 (ja) 1993-09-30 2004-03-08 株式会社先端生命科学研究所 ＰＴＨｒＰアンタゴニスト活性を有するポリペプチド及びそれを含むカルシウム代謝治療薬
JPH07316195A (ja) 1994-05-25 1995-12-05 Nippon Kayaku Co Ltd 新規なＰＴＨｒＰ関連ペプチド及びその用途
CO4410206A1 (es) 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
ES2179929T3 (es) 1995-01-23 2003-02-01 Xenotech Inc Procedimiento que trata de inhibir la osteolisis y las metastasis.
US5993817A (en) 1995-01-23 1999-11-30 Xenotech Method to ameliorate osteolysis and metastasis
US5626845A (en) 1995-01-23 1997-05-06 Xenotech Incorporated Method to ameliorate osteolysis and metastasis
WO1996025944A1 (fr) 1995-02-20 1996-08-29 Yukio Kato Remedes contre la polyarthrite rhumatoide et les affections articulaires inflammatoires
WO1996026737A1 (en) 1995-03-01 1996-09-06 Creative Biomolecules, Inc. Morphogen-induced dentine regeneration
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
US5660826A (en) 1995-06-06 1997-08-26 The Regents Of The University Of California Therapeutic sepsis treatment using antagonists to PTHrP
AU6172196A (en) 1995-07-20 1997-02-18 Icn Pharmaceuticals Compounds and methods related to parathyroid hormone-like protein
EP1166796A3 (en) 1996-02-01 2002-03-06 Chugai Seiyaku Kabushiki Kaisha Agents for preventing and treating thrombocytopenia
DE69737656T2 (de) 1996-09-10 2008-01-03 Theodor Kocher Institut Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
EP0962467A4 (en) 1996-09-26 2002-10-30 Chugai Pharmaceutical Co Ltd ANTIBODIES AGAINST HUMAN PARATHORMON RELATED PEPTIDES
JP4228089B2 (ja) 1997-03-11 2009-02-25 株式会社ニコン 過電流検知機構およびそれを用いた電子閃光装置
JP4372240B2 (ja) 1997-05-15 2009-11-25 中外製薬株式会社 悪液質治療剤
ATE361099T1 (de) 1997-05-15 2007-05-15 Chugai Pharmaceutical Co Ltd Heilmittel für kachexie
JP3791863B2 (ja) 1997-07-04 2006-06-28 株式会社フジタ 鉄筋コンクリート系建物の制震構造
JP4414494B2 (ja) 1998-02-03 2010-02-10 旭化成ファーマ株式会社 白血球減少症の予防剤および治療剤
ES2302374T3 (es) 1998-05-05 2008-07-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Compuesto selectivo de receptores pth2.
JP2000080100A (ja) 1998-06-17 2000-03-21 Japan Tobacco Inc 副甲状腺ホルモン関連タンパクに対するヒトモノクローナル抗体
CA2332128A1 (en) 1998-06-26 2000-01-06 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hypercalcemic crisis

Also Published As

Publication number Publication date
EP0962467A1 (en) 1999-12-08
WO1998013388A1 (fr) 1998-04-02
RU2198220C2 (ru) 2003-02-10
SK40599A3 (en) 2000-06-12
TR199900666T2 (xx) 1999-06-21
US20080095772A1 (en) 2008-04-24
CA2266332C (en) 2012-01-03
EP0962467A4 (en) 2002-10-30
HK1096974A1 (en) 2007-06-15
NO991449D0 (no) 1999-03-25
HUP9904177A3 (en) 2001-10-29
CZ106299A3 (cs) 1999-08-11
KR100847441B1 (ko) 2008-07-21
CN1237983A (zh) 1999-12-08
KR20060006981A (ko) 2006-01-20
US7358355B2 (en) 2008-04-15
BR9713294A (pt) 2000-10-17
US20050136057A1 (en) 2005-06-23
IL129164A0 (en) 2000-02-17
TW509697B (en) 2002-11-11
HUP9904177A2 (hu) 2000-03-28
US6903194B1 (en) 2005-06-07
AU4397297A (en) 1998-04-17
US7842790B2 (en) 2010-11-30
IL129164A (en) 2007-05-15
AU744146B2 (en) 2002-02-14
CN100335501C (zh) 2007-09-05
CA2266332A1 (en) 1998-04-02

Similar Documents

Publication Publication Date Title
NO991449D0 (no) Antistoff mot human parathormon-relaterte peptider
NO985464D0 (no) Konsentrert antistoffpreparat
NO20004133D0 (no) Antistoffer mot human CD40
IS5375A (is) KAY-nýstárlegt ónæmisprótín
DE69635900D1 (de) Angetriebene gegenhalte-zange
NO980915D0 (no) Rekombinante anti-CD4-antistoff egnet for human terapi
ATE192643T1 (de) Verbunddamenbinde
NO985680L (no) Peptidderivater
BR9610239A (pt) Proteínas de fusão-alérgeno-xcd32
FI970168A0 (fi) Peptidejä
NO983849L (no) Peptidderivater
NO980719L (no) Tetningskjerne
NO980104D0 (no) Sandwichkonstruksjon
NO983800D0 (no) Makrocykliske peptider for anvendelse mot trombin-relaterte mangler
BR9606756A (pt) Peptídeo
TR199701666A3 (tr) Sismanliga karsi proteinler
DK0950063T3 (da) Flergrenede peptidkonstruktioner
NO981052D0 (no) Peptidderivater
NO981051D0 (no) Peptidderivater
BR9709080A (pt) Anticorpo monoclonal anti-MP52 humano
DE69434900D1 (de) Menschliche chemokin-polypeptide
KR980001290U (ko) 만년도장
BR1100812A (pt) Peptìdeo
SE9504467D0 (sv) Peptide
KR970040927U (ko) 과급 장치

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application